N/A N=4 Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
Nephrogenic Diabetes Insipidus
Primary: 24h Urine Volume — 6475; 4178; 6652; 4188 urine volume in mL/d
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria
Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…
Phase 4 N=16 Renal and Hormonal Effects of Pioglitazone
Diabetes · Hypertension
Primary: Effects of Pioglitazone on Renal Hemodynamics — 68.0; 62.4 ml/min/1.73m2
Phase 4 N=36 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Type 2 Diabetes
Primary: Percent Change in Fractional Excretion of Sodium (FENA) — 41; -5.0 percentage of change — p==0.012
Phase 4 N=395 Nephropathy In Type 2 Diabetes and Cardio-renal Events
Diabetic Nephropathy
Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05
Phase 3 N=89 Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
Nocturnal Enuresis
Primary: Change in the Number of Wet Nights Between Baseline and Treatment Period II — 3.264; 1.451 wet nights — p=0.009
Phase 2 N=83 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Phase 4 N=162 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy
Kidney Failure
Primary: The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications. — 25; 11 participants — p=0.01
Phase 4 N=34 Glargine Versus NPH in Patients With Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045
Phase 2 N=50 Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
Diabetes Mellitus, Type 1 · Nephropathy · Diabetic Nephropathies
Primary: Copeptin Levels — 8.3 pmol/L
Phase 4 N=44 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Diabetic Nephropathies
Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min
Phase 2 N=271 Sodium Chloride and Contrast Nephropathy
Kidney Failure, Chronic · Kidney Failure, Acute · Heart Failure
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants
Phase 2 N=160 Chlorthalidone in Chronic Kidney Disease
Renal Insufficiency, Chronic · Hypertension
Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 2 N=30 A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Primary: Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration. — 3.6; 5.3; 7.9 mmol/L
Phase 3 N=34 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Primary: Change in Mean Serum Copeptin From Baseline (a Reflection of Endogenous Vasopressin Production) at Week 2 — -0.86; 0.39 pmole/L — p=<0.01
Phase 4 N=34 Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure
Heart Failure
Primary: Acetazolamide Arm: Natriuresis 24 h — 324; 300; 211; 190 mmol — p=0.515
Phase 2 N=34 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Diabetic Nephropathy
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change
Phase 4 N=40 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Congestive Heart Failure
Primary: Change in Body Weight at 48 Hours — -3.3; -0.8 pounds — p=0.094
N/A N=168 Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Fibrosis · Kidney Failure · Renal Insufficiency
Primary: Number of Participants Who Developed Nephrogenic Systemic Fibrosis (NSF), Based on Diagnostically Specific Clinical and Histopathological Information-cohort Analysis and…
Phase 2 N=12 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
N/A N=540 Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
Renal Insufficiency
Primary: Number of Patients With Moderate to Severe Renal Impairment Who Develop Nephrogenic Systemic Fibrosis (NSF) After Administration of Dotarem — 0 Participants
N/A N=13 Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
Obesity-induced Hyperfiltration
Primary: Change in GFR (ml/Min) — 151; 152; 120; 150 ml/min
Phase 4 N=47 Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
Hypertension
Primary: Sympathetic Nerve Activity — 46; 40; 49; 42 bursts/min
Phase 4 N=85 Inpatient Diabetes on Corticosteroids
Diabetes Mellitus
Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl
N/A N=17 Renal Denervation for Management of Drug-Resistant Hypertension
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement) — 0.7; -21.7 mmHg — p=0.018
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
Phase 4 N=60 Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients
Disorders Associated With Peritoneal Dialysis
Primary: Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor — 1.49; 1.89 IR score
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
Phase 4 N=72 Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Diabetes Mellitus, Type 2
Primary: GFR (Glomerular Filtration Rate) Change After Treatment — 22; 1; 8; 0 ml/min/1.73m^2